ArticleMultiple sclerosis and related disorders2022
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19.
Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis.European journal of medical research · 2024Pooled it
- Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022Pooled it
- Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?Multiple sclerosis and related disorders · 2022Pooled it
- Central nervous system manifestations following vaccination against COVID-19.Brain, behavior, & immunity - health · 2024Review
- Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases.Vaccine: X · 2023Article
- COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece.Journal of clinical medicine · 2023Article
- Review
- Relapse of neuromyelitis optica spectrum disorder after BNT162b2 mRNA Covid-19 vaccination.eNeurologicalSci · 2023Article
- Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.Journal of neurology · 2023Article
- Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Sudden Death Associated With Possible Flare-Ups of Multiple Sclerosis After COVID-19 Vaccination and Infection: A Case Report and Literature Review.Journal of Korean medical science · 2023Review
- New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review.Frontiers in neurology · 2023Review
- Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.Frontiers in immunology · 2023Article
- Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination.Frontiers in neurology · 2023Article
- Fatal neuromyelitis optica after COVID-19 vaccination.Multiple sclerosis and related disorders · 2022Article
- Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.Multiple sclerosis and related disorders · 2022Observational
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.Multiple sclerosis and related disorders · 2022Observational
- Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.Multiple sclerosis and related disorders · 2022Article
- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.Frontiers in immunology · 2022Review
Corrections and comments
- Retraction · 2025-01-09Concerns/Issues about Results and/or Conclusions · Error in Text · Investigation by Third Party · · see also: https://pubpeer.com/publications/AE21ACD2CF589D296EE56D8EACBFE4
- Retracted
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These patients had been stable for a median period of six years, with no evidence of disease activity and no change in their medication. After a median of 13 days (7 to 25 days) from vaccination, they developed a new relapse with increased disability and new lesions on magnetic resonance imaging. Although this association may be rare, it might be an adverse event of AZD1222.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.